Hydralazine
Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026
Hydralazine is a direct arteriolar vasodilator used for hypertension and heart failure. The A-HeFT trial demonstrated significant mortality benefit when combined with isosorbide dinitrate (BiDil) in self-identified Black patients with heart failure. Also used for hypertensive emergencies in pregnancy.
Exploratory record, not a reviewed medical publication.
See the editorial and medical-review policies for the publication gate.
This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.
What the research says.
A quick, data-only summary. The full evidence, dosing, and sources are below.
Hydralazine is a direct arteriolar vasodilator used for hypertension and heart failure. NutriStack rates the supporting evidence as strong. Common adult dosing is 25–100 mg 2–3 times daily (HF combination: 37.5 mg three times daily with ISDN) (as prescribed by your physician), though a prescriber sets the actual dose. With long-term use it can deplete vitamin b6. This profile indexes 10 sources.
The bottom line
Evidence rating strong. Most-documented uses: reduces mortality in black patients with hfref (a-heft, combined with isdn), direct arteriolar vasodilation reduces afterload, safe in pregnancy for hypertension management. 10 sources indexed (2003–2025), with 0 interaction records on file.
How it works, mechanistically.
Core mechanism
Directly relaxes arteriolar smooth muscle through incompletely understood mechanisms, possibly involving interference with calcium transport, increased nitric oxide release, or activation of potassium channels. Reduces peripheral resistance without significant venous dilation. Causes reflex tachycardia and increased cardiac output. Combined with nitrates, the hydralazine-nitrate combination improves NO bioavailability by scavenging reactive oxygen species.
Dosing & protocol.
Food enhances bioavailability; undergoes extensive first-pass hepatic metabolism via acetylation (metabolism rate depends on acetylator phenotype)
What it depletes.
Nutrients this medication can lower over time, and what to replace.
Vitamin B6
ModerateHydralazine can antagonize pyridoxine metabolism and has been linked to pyridoxine-deficiency neuropathy during prolonged therapy.
Full safety detail.
Side effects
- Reflex tachycardia
- Headache
- Flushing
- Palpitations
- Dizziness
- Drug-induced lupus-like syndrome (dose-related, >200 mg/day)
- Peripheral neuropathy (pyridoxine-responsive)
- Sodium and water retention
Sources, by evidence tier.
Numbered references. Citations throughout the page link here.
Meta-analyses & systematic reviews
5- 1Efficacy and Safety of Nifedipine Compared to Intravenous Hydralazine for Severe Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-Analysis of Randmomized Controlled TrialsPMIDGovindasamy V, Kamel MA, Volucke G et al. · Medical sciences (Basel, Switzerland) · 2025
Govindasamy V, Kamel MA, Volucke G et al.. Efficacy and Safety of Nifedipine Compared to Intravenous Hydralazine for Severe Hypertensive Disorders in Pregnancy: A Systematic Review and Meta-Analysis of Randmomized Controlled Trials. Medical sciences (Basel, Switzerland). 2025
- 2Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trialsPMIDGonçalves OR, Bendaham LCAR, Simoni GH et al. · European journal of obstetrics, gynecology, and reproductive biology · 2024
Gonçalves OR, Bendaham LCAR, Simoni GH et al.. Comparative efficacy and safety between intravenous labetalol and intravenous hydralazine for hypertensive disorders in pregnancy: A systematic review and meta-analysis of 19 randomized controlled trials. European journal of obstetrics, gynecology, and reproductive biology. 2024
- 3The flipside of hydralazine in pregnancy: A systematic review and meta-analysisPMIDAntza C, Dimou C, Doundoulakis I et al. · Pregnancy hypertension · 2020
Antza C, Dimou C, Doundoulakis I et al.. The flipside of hydralazine in pregnancy: A systematic review and meta-analysis. Pregnancy hypertension. 2020
- 4Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic reviewPMIDFarag M, Mabote T, Shoaib A et al. · International journal of cardiology · 2015
Farag M, Mabote T, Shoaib A et al.. Hydralazine and nitrates alone or combined for the management of chronic heart failure: A systematic review. International journal of cardiology. 2015
- 5Hydralazine for treatment of severe hypertension in pregnancy: meta-analysisPMIDMagee LA, Cham C, Waterman EJ et al. · BMJ (Clinical research ed.) · 2003
Magee LA, Cham C, Waterman EJ et al.. Hydralazine for treatment of severe hypertension in pregnancy: meta-analysis. BMJ (Clinical research ed.). 2003
Reference material
5- 6Taylor AL et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure (A-HeFT). N Engl J Med. 2004.Source linkedPMID
- 7Cohn JN et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure (V-HeFT I). N Engl J Med. 1986.Source linkedPMID
- 8Singh A et al. Efficacy of pharmacological agents for management of post-partum hypertension: A systematic review and network meta-analysis. J Hum Hypertens. 2026.Source linkedPMID
- 9S D, Novri DA, Hamidy Y et al.. Effectiveness of nifedipine, labetalol, and hydralazine as emergency antihypertension in severe preeclampsia: a randomized control trial. F1000Research. 2022Source linkedPMID
- 10Herman LL, Tivakaran VS. Hydralazine. 2026Source linkedPMID
Common questions.
Quick answers about Hydralazine, drawn from the data on this page.
What is Hydralazine?
Hydralazine is a direct arteriolar vasodilator used for hypertension and heart failure. The A-HeFT trial demonstrated significant mortality benefit when combined with isosorbide dinitrate (BiDil) in self-identified Black patients with heart failure. Also used for hypertensive emergencies in pregnancy.
What is Hydralazine used for?
Commonly cited benefits of Hydralazine include: Reduces mortality in Black patients with HFrEF (A-HeFT, combined with ISDN); Direct arteriolar vasodilation reduces afterload; Safe in pregnancy for hypertension management; Alternative for patients intolerant to ACE inhibitors and ARBs. NutriStack rates the overall evidence as strong.
What is a typical dose of Hydralazine?
A typical adult dose of Hydralazine is 25–100 mg 2–3 times daily (HF combination: 37.5 mg three times daily with ISDN) (as prescribed by your physician). The commonly recommended form is Oral tablet or IV/IM injection. These are general ranges, not personalized advice; confirm the right dose with a clinician.
What are the side effects of Hydralazine?
Reported side effects include reflex tachycardia, headache, flushing, palpitations, dizziness, drug-induced lupus-like syndrome (dose-related, >200 mg/day). This is educational information; check with a healthcare professional before use.
How strong is the evidence for Hydralazine?
NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.
Use this with your stack
Hydralazine in NutriStack.
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.